{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:05:38Z","timestamp":1790996738980,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":29,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ALF (Academic Learning Faculty support)"},{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1111\/ane.12468","type":"journal-article","created":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T07:14:51Z","timestamp":1438586091000},"page":"355-360","source":"Crossref","is-referenced-by-count":30,"title":["Memantine and reduced time with dyskinesia in Parkinson\u2032s Disease"],"prefix":"10.1155","volume":"133","author":[{"given":"K.","family":"Wictorin","sequence":"first","affiliation":[{"name":"Division of Neurology; Department of Clinical Sciences; Sk\u00e5ne University Hospital; Lund University; Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Widner","sequence":"additional","affiliation":[{"name":"Division of Neurology; Department of Clinical Sciences; Sk\u00e5ne University Hospital; Lund University; Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,3]]},"reference":[{"key":"10.1111\/ane.12468-BIB0001|ane12468-cit-0001","first-page":"110","volume-title":"Parkinson\u2032s disease and movement disorders","author":"Tolosa","year":"2007"},{"key":"10.1111\/ane.12468-BIB0002|ane12468-cit-0002","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson\u2032s disease: filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12468-BIB0003|ane12468-cit-0003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","article-title":"Maladaptive striatal plasticity in L-dopa-induced dyskinesia","volume":"183","author":"Cenci","year":"2010","journal-title":"Prog Brain Res"},{"key":"10.1111\/ane.12468-BIB0004|ane12468-cit-0004","volume-title":"Amantadine for dyskinesia in Parkinson's disease (Cochrane review)","author":"Crosby","year":"2003"},{"key":"10.1111\/ane.12468-BIB0005|ane12468-cit-0005","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2032s disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1111\/ane.12468-BIB0006|ane12468-cit-0006","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias. A 1-year follow-up study","volume":"56","author":"Verhagen Metman","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12468-BIB0007|ane12468-cit-0007","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson\u2032s disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0008|ane12468-cit-0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","article-title":"The effect on amantadine on levodopa-induced dyskinesias in Parkinson\u2032s disease: a double-blind, placebo-controlled study","volume":"23","author":"Snow","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1111\/ane.12468-BIB0009|ane12468-cit-0009","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson\u2032s disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12468-BIB0010|ane12468-cit-0010","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/mds.23034","article-title":"Long-term antidyskinetic efficacy of amantadine in Parkinson\u2032s disease","volume":"25","author":"Wolf","year":"2010","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0011|ane12468-cit-0011","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure","volume":"10","author":"Fox","year":"2006","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0012|ane12468-cit-0012","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials","volume":"26","author":"Berg","year":"2011","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0013|ane12468-cit-0013","first-page":"367","article-title":"Memantine: a review of studies into its safety and efficacy in treating Alzheimer\u2032s disease and other dementias","volume":"4","author":"Thomas","year":"2009","journal-title":"Clin Interv Aging"},{"key":"10.1111\/ane.12468-BIB0014|ane12468-cit-0014","first-page":"1487","article-title":"Effects of intravenous administration of memantine in parkinsonian patients","volume":"27","author":"Fischer","year":"1977","journal-title":"Arzneimittelforschung"},{"key":"10.1111\/ane.12468-BIB0015|ane12468-cit-0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson\u2032s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12468-BIB0016|ane12468-cit-0016","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson\u2032s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12468-BIB0017|ane12468-cit-0017","first-page":"273","article-title":"Effect of memantine (NMDA antagonist) on Parkinson\u2032s disease: a double-blind crossover randomized study","volume":"22","author":"Merello","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1111\/ane.12468-BIB0018|ane12468-cit-0018","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/1531-8257(200009)15:5<1016::AID-MDS1042>3.0.CO;2-J","article-title":"The use of NMDA antagonist memantine in drug-resistant dyskinesia resulting from L-dopa","volume":"15","author":"Hanagasi","year":"2000","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0019|ane12468-cit-0019","first-page":"2003","article-title":"Memantine can relieve certain symptoms in Parkinson\u2032s disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure","volume":"101","author":"Lokk","year":"2004","journal-title":"L\u00e4kartidningen"},{"key":"10.1111\/ane.12468-BIB0020|ane12468-cit-0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.22917","article-title":"NMDA antagonist memantine improves levodopa-induced dyskinesias and \u201con-off\u201d phenomena in Parkinson\u2032s disease","volume":"25","author":"Varanese","year":"2010","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0021|ane12468-cit-0021","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jgs.12058","article-title":"Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson\u2032s disease dementia","volume":"61","author":"Vidal","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/ane.12468-BIB0022|ane12468-cit-0022","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/jnnp-2012-303182","article-title":"Memantine for axial signs in Parkinson\u2032s disease: a randomised, double-blind, placebo-controlled pilot study","volume":"84","author":"Moreau","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12468-BIB0023|ane12468-cit-0023","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/1531-8257(199905)14:3<448::AID-MDS1010>3.0.CO;2-0","article-title":"Clinical rating of dyskinesias in Parkinson\u2032s disease: use and reliability of a new rating scale","volume":"14","author":"Hagell","year":"1999","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0024|ane12468-cit-0024","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/mds.870120631","article-title":"Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson\u2032s disease","volume":"12","author":"Goetz","year":"1997","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0025|ane12468-cit-0025","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/jnnp.2003.022780","article-title":"Use and interpretation of on\/off diaries in Parkinson\u2032s disease","volume":"75","author":"Reimer","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12468-BIB0026|ane12468-cit-0026","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.parkreldis.2005.05.008","article-title":"Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"11","author":"Pereira da Silva-Junior","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ane.12468-BIB0027|ane12468-cit-0027","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/mds.22495","article-title":"Randomized controlled trial of memantine in dementia associated with Parkinson\u2032s disease","volume":"24","author":"Leroi","year":"2009","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0028|ane12468-cit-0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11055-009-9244-1","article-title":"Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson\u2032s disease complicated by dementia","volume":"40","author":"Litvinenko","year":"2010","journal-title":"Neurosci Behav Physiol"},{"key":"10.1111\/ane.12468-BIB0029|ane12468-cit-0029","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","article-title":"Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies","volume":"21","author":"Danysz","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"issue":"Suppl 4","key":"10.1111\/ane.12468-BIB0030|ane12468-cit-0030","first-page":"S13","article-title":"Amantadine and other antiglutamate agents","volume":"17","author":"Lang","year":"2002","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12468-BIB0031|ane12468-cit-0031","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.parkreldis.2010.12.003","article-title":"Memantine for non-motor features of Parkinson\u2032s disease: a double-blind placebo controlled exploratory pilot trial","volume":"17","author":"Ondo","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ane.12468-BIB0032|ane12468-cit-0032","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson\u2032s disease. The Amandysk trial","volume":"82","author":"Ory-Magne","year":"2014","journal-title":"Neurology"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12468","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12468\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:48:50Z","timestamp":1671540530000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,3]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12468","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8,3]]}}}